DOI: 10.1002/14651858.CD015092.pub2 Tirzepatide for adults living with obesity by Juan VA Franco, Yang Guo, Lucia B Varela, Zakariya Aqra, Murad Alhalahla, Mauricio Medina Rodriguez, Edison Leonardo Salvador Oscco, Bernarda Patio Araujo, Susan Banda, Camila Micaela Escobar Liquitay, Javier Bracchiglione, Nicols Meza and Eva Madrid, 30 October 2025, Cochrane Database of Systematic Reviews
The updated CT-388 data puts it essentially neck-and-neck with retatrutide at the 48-week mark, and ahead of tirzepatide's 72-week result
This is where we are different
Individuals who will respond well to Retatrutide generally show meaningful blood sugar changes by this point
This dietary pattern not only contributes to obesity but also to dyslipidemia and impaired glucose metabolism, worsening diabetes
Practical factors also determine timeline: consistent weekly injections produce faster results than sporadic dosing, adequate protein intake preserves muscle during weight loss, and moderate exercise amplifies fat loss